BRCA2 and neoplasm: Compared to vehicle treatment, MMC treatment potently inhibited the in vivo growth of heterozygous BRCA2 monoallelic mutant SNU-1 tumor xenografts in immune-deficient mice (p < 0.01, Fig. 3j top) and significantly improved the survival rate of the mice (p < 0.05, Fig. 3j bottom).